Literature DB >> 16083215

Epilepsia partialis continua as a manifestation of hyperglycemia.

Supachai Paiboonpol1.   

Abstract

A review of 22 patients who presented with the syndrome of epilepsia partialis continua as symptoms of hyperglycemia and occurred during the phase of hyponatremia and mild hyperosmolality. Epilepsia partialis continua persisted for an average of 9 days,and its duration correlated with the degree of hyponatremia, low blood urea nitrogen(BUN) and measured serum osmolality. In all patients, epilepsia partialis continua was the first symptom leading to the diagnosis of diabetes mellitus. The epilepsia partialis continua ceased by normalization of blood glucose level. All patients survived and did not have any complications. The majority of the patients had evidence of a localized structural brain lesions and low serum sodium. Metabolic abnormalities including hyperglycemia,mild hyperosmolality and hyponatremia contribute to the development of epilepsiapartialis continua in an area of focal brain damage. It is important to determine blood glucose levels in all cases of epilepsia partialis continua.

Entities:  

Mesh:

Year:  2005        PMID: 16083215

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  3 in total

1.  Recurrent Facial Focal Seizures With Chronic Striatopathy and Caudate Atrophy-A Double Whammy in an Elderly Woman With Diabetes Mellitus.

Authors:  Subhankar Chatterjee; Ritwik Ghosh; Umesh Kumar Ojha; Payel Biswas; Julián Benito-León; Souvik Dubey
Journal:  Neurohospitalist       Date:  2021-07-23

2.  Post-operative nonketotic hyperglycemic induced focal motor status epilepticus related to treatment with corticosteroids following standard anterior temporal lobectomy.

Authors:  Andrew Zillgitt; Abdullah Alshammaa; Muhammad Salim Kahn; Sarah Madani; Salman Zahoor; Ellen L Air
Journal:  Epilepsy Behav Case Rep       Date:  2018-10-02

3.  Cortical blindness with absent visually evoked potential in non-ketotic hyperglycemia.

Authors:  Arvind Gupta; Vasudev Anand Rao; Datta Gulnar Pandian; Ashok Kumar Das
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.